Home > Investors
Investor Relations Home
E-mail Page Print Page RSS Feeds E-mail Alerts IR Contacts Financial Tear Sheet 
About Us
Webcast ImageWebcast - Live
Q1 2015 The Medicines Company Earnings Conference Call
05/05/15 at 8:30 a.m. ET
Webcast ImageWebcast - Replay
The Medicines Company at Cowen and Company 35th Annual Health Care Conference
03/03/15 at 8:40 a.m. ET
Webcast ImageWebcast - Replay
The Medicines Company at RBC Capital Markets 2015 Healthcare Conference
02/25/15 at 8:30 a.m. ET
Webcast ImageWebcast - Replay
Q4 2014 The Medicines Company Earnings Conference Call
02/18/15 at 8:30 a.m. ET
Corporate Profile
The Medicines Company provides medical solutions to improve health outcomes for patients in acute and intensive care hospitals worldwide. These solutions comprise medicines and knowledge that directly impact the survival and well-being of critically ill patients.
Stock Quote
MDCO (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$27.07
Change (%) Stock is Up 1.46 (5.70%)
Volume1,537,742
Data as of 05/01/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
DateTitle 
04/30/15The Medicines Company Announces FDA Approval of RAPLIXA™ (Fibrin Sealant), the First and Only Powdered Fibrin Sealant Ready-to-Use for Mild to Moderate Surgical Bleeding
PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 30, 2015-- The Medicines Company (NASDAQ:MDCO) announced today the U.S. Food and Drug Administration (FDA) has approved RAPLIXA™ (fibrin sealant) and the RaplixaSpray™ device to provide adjunctive hemostasis for mild to moderate bleeding in adults undergoing surgery when control of bleeding by standard surgical techniques (such as suture, ligature and cautery) is ineffective or impractical. According... 
Printer Friendly Version
04/30/15The Medicines Company Announces FDA Approval of IONSYS® (fentanyl iontophoretic transdermal system) for the Management of Acute Post-Operative Pain for Adult Patients in the Hospital
IONSYS® is the first needle-free, patient-controlled, pre-programmed fentanyl delivery system PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 30, 2015-- The Medicines Company (NASDAQ:MDCO) today announced that the U.S. Food and Drug Administration (FDA) has approved IONSYS® (fentanyl iontophoretic transdermal system), the first needle-free, patient-controlled, pre-programmed fentanyl delivery system, for the short-term management of acute post-operati... 
Printer Friendly Version
04/21/15The Medicines Company to Announce First Quarter Financial Results on Tuesday, May 5, 2015
Conference Call to be held at 8:30 a.m. Eastern Time PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 21, 2015-- The Medicines Company (NASDAQ:MDCO) has scheduled its quarterly conference call for Tuesday, May 5th at 8:30 a.m. Eastern Time to discuss first quarter financial results and operational developments. The conference call will be available via phone and webcast. The dial-in information is listed below: Domestic Dial In: ... 
Printer Friendly Version
04/20/15FDA Approves New Formulation of MINOCIN® (minocycline) for Injection
- Grants Qualified Infectious Disease Product (QIDP) Designation for new potential indications, including hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP) and certain gram-negative infections in cystic fibrosis patients - Third QIDP Designation for Company’s Infectious Disease Portfolio PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 20, 2015-- The Medicines Company (NASDAQ:MDCO) today announced that the ... 
Printer Friendly Version
Upcoming Events
DateTitle
05/05/15 8:30 a.m. ET
Q1 2015 The Medicines Company Earnings Conference Call

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.